Abstract
Background
Diabetes remission is not observed in all obese patients with type 2 diabetes submitted to bariatric surgery. Relapses occur in patients in whom remission is achieved. We investigated the factors associated with long-term (≥3 years) remission and relapse of type 2 diabetes after Roux-en-Y gastric bypass (RYGB) in these patients.
Methods
By a retrospective review, we analyzed data from 254 patients with type 2 diabetes who had undergone RYGB from May 2000 to November 2011 and had at least 3 years of follow-up. The criteria for remission and relapse of type 2 diabetes followed the current American Diabetes Association recommendations.
Results
Remission was achieved in almost 82% of participants (69.7% complete, and 12.2% partial remission). Of these, 12% relapsed within a mean follow-up of 5.1 ± 2.0 years after surgery. Predictors of complete remission were younger age, better preoperative glycemic control, and shorter diabetes duration. Preoperative insulin use was associated with a ninefold increase in the relapse hazard (HR = 9.1 (95% CI: 3.3–25.4)). Use of two or more oral anti-diabetic agents increased the relapse hazard sixfold (HR = 6.1 (95% CI: 1.8–20.6)). Eighteen point one percent of patients did not achieve any remission during follow-up. However, they exhibited significant improvements in glycemic control.
Conclusions
These data indicate that RYGB should not be delayed when remission of type 2 diabetes is a therapeutic goal, and also suggest that the best possible metabolic control should be sought in obese patients who may eventually be candidates for RYGB.
Similar content being viewed by others
References
Aguiree F, Brown A, Cho N, et al. IDF Diabetes Atlas. 2013; doi:10.1016/j.diabres.2009.10.007.
Kahn SE, Hull RL, Utzschneider KM. Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature. 2006;444:840–6. doi:10.1038/nature05482.
American Diabetes Association. Prevention or Delay of Type 2 Diebetes. Diabetes Care 2017;40(Suppl. 1):S44-S47. doi:10.2337/dc17-S008.
Rubino F, Nathan DM, Eckel RH, et al. Metabolic surgery in the treatment algorithm for type 2 diabetes: a joint statement by international diabetes organizations. Diabetes Care. 2016;39:861–77. doi:10.2337/dc16-0236.
Mingrone G, Panunzi S, De Gaetano A, et al. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med. 2012;366:1577–85. doi:10.1056/NEJMoa1200111.
Schauer PR, Mingrone G, Ikramuddin S, et al. Clinical outcomes of metabolic surgery: efficacy of glycemic control, weight loss, and remission of diabetes. Diabetes Care. 2016;39:902–11. doi:10.2337/dc16-0382.
Keating CL, Dixon JB, Moodie ML, et al. Cost-efficacy of surgically induced weight loss for the management of type 2. Diabetes Care. 2009;32:4580–4. doi:10.2337/dc08-1748.
Hoerger TJ, Zhang P, Segel JE, et al. Cost-effectiveness of bariatric surgery for severely obese adults with diabetes. Diabetes Care. 2010;33:1933–9. doi:10.2337/dc10-0554.
Courcoulas AP, Belle SH, Neiberg RH, et al. Three-year outcomes of bariatric surgery vs lifestyle intervention for type 2 diabetes mellitus treatment. JAMA Surg. 2015;15213:1–9. doi:10.1001/jamasurg.2015.1534.
Sjöström L, Peltonen M, Jacobson P, et al. Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications. JAMA. 2014;311:2297–304. doi:10.1001/jama.2014.5988.
Tice JA, Karliner L, Walsh J, et al. Gastric banding or bypass? A systematic review comparing the two most popular bariatric procedures. Am J Med. 2008;121:885–93. doi:10.1016/j.amjmed.2008.05.036.
Lee W-J, Chong K, Lin Y-H, et al. Laparoscopic sleeve gastrectomy versus single anastomosis (mini-) gastric bypass for the treatment of type 2 diabetes mellitus: 5-year results of a randomized trial and study of incretin effect. Obes Surg. 2014:1552–62. doi:10.1007/s11695-014-1344-5.
Buse JB, Caprio S, Cefalu WT, et al. How do we define cure of diabetes? Diabetes Care. 2009;32:2133–5. doi:10.2337/dc09-9036.
DiGiorgi M, Rosen DJ, Choi JJ, et al. Re-emergence of diabetes after gastric bypass in patients with mid- to long-term follow-up. Surg Obes Relat Dis. 2010;6:249–53. doi:10.1016/j.soard.2009.09.019.
Hall TC, Pellen MGC, Sedman PC, et al. Preoperative factors predicting remission of type 2 diabetes mellitus after Roux-en-Y gastric bypass surgery for obesity. Obes Surg. 2010;20:1245–50. doi:10.1007/s11695-010-0198-8.
Hamza N, Abbas MH, Darwish A, et al. Predictors of remission of type 2 diabetes mellitus after laparoscopic gastric banding and bypass. Surg Obes Relat Dis. 2011;7:691–6. doi:10.1016/j.soard.2010.03.292.
Pournaras DJ, Osborne A, Hawkins SC, et al. Remission of type 2 diabetes after gastric bypass and banding: mechanisms and 2 year outcomes. Ann Surg. 2010;252:966–71. doi:10.1097/SLA.0b013e3181efc49a.
Kim MK, Lee HC, Kwon H-S, et al. Visceral obesity is a negative predictor of remission of diabetes 1 year after bariatric surgery. Obesity (Silver Spring). 2011;19:1835–9. doi:10.1038/oby.2011.205.
Lee WJ, Chong K, Chen JC, et al. Predictors of diabetes remission after bariatric surgery in Asia. Asian J Surg. 2012;35:67–73. doi:10.1016/j.asjsur.2012.04.010.
Blackstone R, Bunt JC, Cortés MC, et al. Type 2 diabetes after gastric bypass: remission in five models using HbA1c, fasting blood glucose, and medication status. Surg Obes Relat Dis. 2012;8:548–55. doi:10.1016/j.soard.2012.05.005.
Dixon JB, Chuang L-M, Chong K, et al. Predicting the glycemic response to gastric bypass surgery in patients with type 2 diabetes. Diabetes Care. 2013;36:20–6. doi:10.2337/dc12-0779.
Robert M, Ferrand-Gaillard C, Disse E, et al. Predictive factors of type 2 diabetes remission 1 year after bariatric surgery: impact of surgical techniques. Obes Surg. 2013;23:770–5. doi:10.1007/s11695-013-0868-4.
Iacobellis G, Xu C, Campo RE, et al. Predictors of short-term diabetes remission after laparoscopic Roux-en-Y gastric bypass. Obes Surg. 2014;25:782–7. doi:10.1007/s11695-014-1477-6.
Zenti MG, Rubbo I, Ceradini G, et al. Clinical factors that predict remission of diabetes after different bariatric surgical procedures: interdisciplinary group of bariatric surgery of Verona (G.I.C.O.V.). Acta Diabetol. 2015; doi:10.1007/s00592-015-0738-8.
Kadera BE, Lum K, Grant J, et al. Remission of type 2 diabetes after Roux-en-Y gastric bypass is associated with greater weight loss. Surg Obes Relat Dis. 2009;5:305–9. doi:10.1016/j.soard.2009.02.007.
Chikunguwo SM, Wolfe LG, Dodson P, et al. Analysis of factors associated with durable remission of diabetes after Roux-en-Y gastric bypass. Surg Obes Relat Dis. 2010;6:254–9. doi:10.1016/j.soard.2009.11.003.
Jiménez A, Casamitjana R, Flores L, et al. Long-term effects of sleeve gastrectomy and Roux-en-Y gastric bypass surgery on type 2 diabetes mellitus in morbidly obese subjects. Ann Surg. 2012;256:1. doi:10.1097/SLA.0b013e318262ee6b.
Aarts EO, Janssen J, Janssen IMC, et al. Preoperative fasting plasma C-peptide level may help to predict diabetes outcome after gastric bypass surgery. Obes Surg. 2013;23:867–73. doi:10.1007/s11695-013-0872-8.
Ramos-Levi A, Sanchez-Pernaute A, Matia P, et al. Diagnosis of diabetes remission after bariatic surgery may be jeopardized by remission criteria and previous hypoglycemic treatment. Obes Surg. 2013;23:1520–6. doi:10.1007/s11695-013-0995-y.
Arterburn DE, Bogart A, Sherwood NE, et al. A multisite study of long-term remission and relapse of type 2 diabetes mellitus following gastric bypass. Obes Surg. 2013;23:93–102. doi:10.1007/s11695-012-0802-1.
Brethauer SA, Aminian A, Romero-Talamás H, et al. Can diabetes be surgically cured? Long-term metabolic effects of bariatric surgery in obese patients with type 2 diabetes mellitus. Ann Surg. 2013;258:628–36–7. doi:10.1097/SLA.0b013e3182a5034b.
Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. Circulation. 2014;129:S1–45. doi:10.1161/01.cir.0000437738.63853.7a.
James PA, Oparil S, Carter BL, et al. Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311:507–20. doi:10.1001/jama.2013.284427.
Inzucchi SE, Bergenstal RM, Buse JB, et al. Classification and diagnosis of diabetes. Diabetes Care. 2014;38:S8–16. doi:10.2337/dc15-S005.
Dixon JB, McPhail T, O’Brien PE. Minimal reporting requirements for weight loss: current methods not ideal. Obes Surg. 2005;15:1034–9. doi:10.1381/0960892054621053.
Dogan K, Betzel B, Homan J, et al. Long-term effects of laparoscopic Roux-en-Y gastric bypass on diabetes mellitus, hypertension and dyslipidaemia in morbidly obese patients. Obes Surg. 2014:1835–42. doi:10.1007/s11695-014-1310-2.
Mingrone G, Panunzi S, De Gaetano A, et al. Bariatric-metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an open-label, single-centre, randomised controlled trial. Lancet. 2015;386:964–73. doi:10.1016/S0140-6736(15)00075-6.
Nannipieri M, Mari A, Anselmino M, et al. The role of β-cell function and insulin sensitivity in the remission of type 2 diabetes after gastric bypass surgery. J Clin Endocrinol Metab. 2011;96:E1372–9. doi:10.1210/jc.2011-0446.
Schauer PR, Burguera B, Ikramuddin S, et al. Effect of laparoscopic Roux-en Y gastric bypass on type 2 diabetes mellitus. Ann Surg. 2003;238:467–84–5. doi:10.1097/01.sla.0000089851.41115.1b.
Svane MS, Madsbad S. Bariatric surgery—effects on obesity and related co-morbidities. Curr Diabetes Rev. 2014;10:208–14.
Arterburn D, Schauer DP, Wise RE, et al. Change in predicted 10-year cardiovascular risk following laparoscopic Roux-en-Y gastric bypass surgery. Obes Surg. 2009;19:184–9. doi:10.1007/s11695-008-9534-7.
The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329:977–86.
Heller SR. A summary of the ADVANCE trial. Diabetes Care. 2009;32(Suppl 2):1–5. doi:10.2337/dc09-S339.
Isbell JM, Tamboli RA, Hansen EN, et al. Early improvements in insulin sensitivity. Diabetes Care. 2010;33:1438–42. doi:10.2337/dc09-2107.
Madsbad S, Holst JJ. GLP-1 as a mediator in the remission of type 2 diabetes after gastric bypass and sleeve gastrectomy surgery. Diabetes. 2014;63:3172–4. doi:10.2337/db14-0935.
Manning S, Pucci A, Batterham RL. GLP-1: a mediator of the beneficial metabolic effects of bariatric surgery? Physiology. 2015;30:50–62. doi:10.1152/physiol.00027.2014.
Holst JJ. Enteroendocrine secretion of gut hormones in diabetes, obesity and after bariatric surgery. Curr Opin Pharmacol. 2013;13:983–8. doi:10.1016/j.coph.2013.09.014.
Still CD, Wood GC, Benotti P, et al. Preoperative prediction of type 2 diabetes remission after Roux-en-y gastric bypass surgery: retrospective cohort study. Lancet Diabetes Endocrinol. 2014;2:38–45. doi:10.1016/j.jsbmb.2011.07.002.Identification.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
This study received funding from the Brazilian National Research and Development Council (CNPq).
Conflict of Interest
Dr. Lopes Preto de Oliveira was the recipient of a grant from the Brazilian National Research and Development Council (CNPq); Gianluca Pioli Martins was the recipient of a grant from the Brazilian National Research and Development Council (CNPq); Dr. Rizzolli has nothing to disclose; Dr. Mottin has nothing to disclose; Dr. Friedman reports grants from this study. It received funding from the Brazilian National Research and Development Council (CNPq) during the conduct of the study.
Ethical Approval
All procedures were in accordance with the ethical standards of the institutional and/or national research committee and the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed Consent
Does not apply
Electronic Supplementary Material
ESM 1
(DOCX 24kb)
Rights and permissions
About this article
Cite this article
de Oliveira, V.L.P., Martins, G.P., Mottin, C.C. et al. Predictors of Long-Term Remission and Relapse of Type 2 Diabetes Mellitus Following Gastric Bypass in Severely Obese Patients. OBES SURG 28, 195–203 (2018). https://doi.org/10.1007/s11695-017-2830-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11695-017-2830-3